Ketanserin plus prostaglandin El (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone

British Journal of Urology

Volumn 77, Issue 5, 1996, Pages 736-739

  Mirone, V ^a   Imbimbo, C ^a   Fabrizio, V ^a   Longo, N ^a   Palmieri, A ^a  

^a NONE   (Italy)

Author keywords

Impotence, intracavernosal injection; Ketanserin; Prostaglandin e l

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; KETANSERIN; PROSTAGLANDIN E1; SEROTONIN ANTAGONIST;

ARTICLE; CORPUS CAVERNOSUM; DOPPLER FLOWMETRY; DRUG EFFICACY; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

ALPROSTADIL; DRUG COMBINATIONS; HUMANS; IMPOTENCE, VASCULOGENIC; INJECTIONS; KETANSERIN; MALE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0030420283     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br I Psychiat 1983; 143: 332
2. Virag R. Intracavernous injection of papaverine lor erection failure. Letter to the editor. Lancet 1982: 2: 938
3. Zorgniotti AW. Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogcnic impotence. / Ural 1985; 135: 39
4. lunemann KP. Lue TF. Fournier GR, Tanagho EA. Haemodynamics of papaverine- and phentolamine-induced penile erection. / Urol 1986; 136: 158-60
5. Szasz G. Stevenson RW. Lee L. Sanders HD. Induction of penile erection by intracavernosal injection; a double-blind comparison of phenoxybenzamine versus papaverinephentolamine versus saline. Arch Sex Bchav 1987: 16: 371-8
6. Ishii N, Watanabe H. Irisawa C et al. Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin El for organic impotence, jap }Urol 1986; 77: 954
7. Lue TF. Stackl W. Intracavernous injection of prostaglandin El. read at the Progress in Impotence, Workshops and Seminars. California. November 12-14. 1987
8. Ishii N. Watanabe H. Irisawa C ft al Treatment of incomplete erection with prostaglandin. ]ap ] Urol 1985; 76: 1708
9. Virag R. Adaiken PG. Effects of prostaglandin El on penile erection and erectile failure. Letter to the editor. / Urol 1987: 137: 1010
10. Hedlund H, Andersson KE. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. / Urol 1985; 134: 1245
11. Halsted DS. Weigel JW. Noble MJ. Mebust WK. Papaverineinduced priapism; 2 case reports. / Urol 1986; 136: 109
12. Hakenberg 0. Wetterauer U. Kopperman U, Luhmann R. Systemic pharmacokinetics of papaverine and phentolamine; comparison of intravenous and intracavernous application. M ] Impôt Res 1990: 2 (suppl 2): 247
13. Earle CM, Keogh EJ. Wisniewski C ft al. Prostaglandin El therapy for impotence, comparison with papaverine. / Urol 1990: 143: 57-9
14. Floth A. Schramek P. Intracavernous injection of prostaglandin El in combination with papaverine; enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin El alone. / Urol 1991; 145: 56-9
15. Symoens J. Are therapeutic effects of ketanserin compatible with serotonergic mechanism? In Clerck F, Vanhoutte PM eds. hydroxitriptaniine in Peripheral Reactions. New York: Raven Press, 1982: 199-212
16. Mirone V. Imbimbo C. Palmieri A, Fabrizio F, Lamberti F. Russo A. A 5-H12 antagonist in intracavernous therapy of erectile dysfunction; ketanserin. Int ] Impôt Res 1992; 4 (suppl 2): 5
17. Amery A, Fagard R. Fiocchi R et al. Ketanserin; a new hypotensive drug? / Cardiovasc Pharmacol 1985: 7 (suppl 7): 176-82
18. Janssen PAJ. Pharmacology of potent and selective S2-serotonergic antagonists. / Cardiovasc Pharmacol 1985: 7 (suppl 7): 2-11
19. Leysen JE. Awouters F, Kennis L et al. Receptor binding profile of R41468. a novel antagonist at 5-H12 receptors. Life Sei 1981; 28: 1015-22
20. Niemegeers CJE, Leysen JE. Laduron I'M. Janssen PAJ. Differential pharmacological and biochemical profiles of serotonin-S2 antagonist. Proe. 14th CI N P Congress. Florence. 1984: 885
21. Kalkman HO, Timmermanns PBMWM. Van Zweiten PA. Characterization of the antihypertensive properties of ketanserin (R 41468) in rats. / Pharmacol Kxp Thcr 1982: 51: 222-7
22. Zabludowski JR. Ball SC,. Robertson JIS. Ketanserin and alpha-2-adrenergic antagonist in humans. / Cnrrfiowisr Pharmacol 1985: 7 (suppl 7): 123-5
23. Donnelly R. Elliot HL. Meredith PA, Reid JL. Acute and chronic ketanserin in essential hypertension: antihyperten-sive mechanism and pharmacokinetics. Br }Clin l'Iwrniiuvl 1987: 24: 599-606